Reslizumab

證據等級: L5

預測適應症: 2 個

Reslizumab: From Severe Eosinophilic Asthma to Thrombocytopenia due to Immune Destruction

One-Sentence Summary

Reslizumab is an anti-IL-5 monoclonal antibody used to treat severe eosinophilic asthma. The TxGNN model predicts it may be effective for Thrombocytopenia due to Immune Destruction, but currently no clinical trials and no supporting literature back this prediction — it is a pure model-derived signal.

Quick Overview

Item	Content
Original Indication	Severe eosinophilic asthma (from repurposing-rationale narrative only; no formal indication/license record available)
Predicted New Indication	Thrombocytopenia due to Immune Destruction
TxGNN Prediction Score	99.53%
Evidence Level	L5
Market Status	Not Marketed (0 authorizations on record)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for reslizumab is not available in this evidence pack. Based on the repurposing rationale that is available, reslizumab is an anti-IL-5 monoclonal antibody that blocks IL-5 from binding its receptor on eosinophils, and is used clinically for severe eosinophilic asthma.

The predicted new indication, immune thrombocytopenia, arises from a fundamentally different pathology — autoantibody-mediated platelet clearance involving B cells, Fc receptors, and splenic macrophages. There is no known direct mechanistic overlap between IL-5/eosinophil biology and this platelet-clearance pathway.

The TxGNN score (99.53%) reflects a graph neural network association only, with no literature or clinical evidence currently connecting reslizumab — or the anti-IL-5 drug class — to immune thrombocytopenia. A related but distinct candidate in this evidence pack, "primary release disorder of platelets" (score 99.25%), is supported by a single review article, but that article discusses mepolizumab (a different anti-IL-5 antibody) in hypereosinophilic syndrome, not reslizumab or platelet disease specifically — offering only a weak class-level analogy rather than direct support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests entirely on a TxGNN model score (Evidence Level L5, decision stage S0) with no clinical trials, no supporting literature, and no established mechanistic link between the IL-5 pathway and immune-mediated platelet destruction. Core safety data (package insert warnings and contraindications) is also missing, which blocks even a preliminary safety assessment.

To proceed, the following is needed:

Package insert warnings/contraindications for reslizumab (currently blocking this evaluation)
Verified mechanism-of-action data for reslizumab
Preclinical or mechanistic studies linking the IL-5/eosinophil pathway to immune thrombocytopenia
Any emerging clinical trial or case-report evidence in ITP or related platelet disorders
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.